These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30655386)

  • 1. Bromodomain and Extra Terminal Protein Inhibitors Promote Pancreatic Endocrine Cell Fate.
    Huijbregts L; Petersen MBK; Berthault C; Hansson M; Aiello V; Rachdi L; Grapin-Botton A; Honore C; Scharfmann R
    Diabetes; 2019 Apr; 68(4):761-773. PubMed ID: 30655386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the immunocytochemical detection of Neurogenin 3 expression in mouse and man.
    Honoré C; Rescan C; Hald J; McGrath PS; Petersen MB; Hansson M; Klein T; Østergaard S; Wells JM; Madsen OD
    Diabetes Obes Metab; 2016 Sep; 18 Suppl 1():10-22. PubMed ID: 27615127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDX1, Neurogenin-3, and MAFA: critical transcription regulators for beta cell development and regeneration.
    Zhu Y; Liu Q; Zhou Z; Ikeda Y
    Stem Cell Res Ther; 2017 Nov; 8(1):240. PubMed ID: 29096722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inhibitor of fibroblast growth factor receptor-1 (FGFR1) promotes late-stage terminal differentiation from NGN3+ pancreatic endocrine progenitors.
    Yamashita-Sugahara Y; Matsumoto M; Ohtaka M; Nishimura K; Nakanishi M; Mitani K; Okazaki Y
    Sci Rep; 2016 Oct; 6():35908. PubMed ID: 27786288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.
    Jones Lipinski RA; Stancill JS; Nuñez R; Wynia-Smith SL; Sprague DJ; Nord JA; Bird A; Corbett JA; Smith BC
    Am J Physiol Regul Integr Comp Physiol; 2024 Jun; 326(6):R515-R527. PubMed ID: 38618911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-site Neurogenin3 Phosphorylation Controls Pancreatic Endocrine Differentiation.
    Azzarelli R; Hurley C; Sznurkowska MK; Rulands S; Hardwick L; Gamper I; Ali F; McCracken L; Hindley C; McDuff F; Nestorowa S; Kemp R; Jones K; Göttgens B; Huch M; Evan G; Simons BD; Winton D; Philpott A
    Dev Cell; 2017 May; 41(3):274-286.e5. PubMed ID: 28457793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET Bromodomain Inhibitors Suppress Inflammatory Activation of Gingival Fibroblasts and Epithelial Cells From Periodontitis Patients.
    Maksylewicz A; Bysiek A; Lagosz KB; Macina JM; Kantorowicz M; Bereta G; Sochalska M; Gawron K; Chomyszyn-Gajewska M; Potempa J; Grabiec AM
    Front Immunol; 2019; 10():933. PubMed ID: 31114581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Neurod1 contributes to the lineage potential of Neurogenin3+ endocrine precursor cells in the pancreas.
    Mastracci TL; Anderson KR; Papizan JB; Sussel L
    PLoS Genet; 2013; 9(2):e1003278. PubMed ID: 23408910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration.
    Russell JO; Ko S; Saggi HS; Singh S; Poddar M; Shin D; Monga SP
    Am J Pathol; 2018 Jun; 188(6):1389-1405. PubMed ID: 29545201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a small molecule that facilitates the differentiation of human iPSCs/ESCs and mouse embryonic pancreatic explants into pancreatic endocrine cells.
    Kondo Y; Toyoda T; Ito R; Funato M; Hosokawa Y; Matsui S; Sudo T; Nakamura M; Okada C; Zhuang X; Watanabe A; Ohta A; Inagaki N; Osafune K
    Diabetologia; 2017 Aug; 60(8):1454-1466. PubMed ID: 28534195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurog3-Independent Methylation Is the Earliest Detectable Mark Distinguishing Pancreatic Progenitor Identity.
    Liu J; Banerjee A; Herring CA; Attalla J; Hu R; Xu Y; Shao Q; Simmons AJ; Dadi PK; Wang S; Jacobson DA; Liu B; Hodges E; Lau KS; Gu G
    Dev Cell; 2019 Jan; 48(1):49-63.e7. PubMed ID: 30620902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurogenin3 initiates stepwise delamination of differentiating endocrine cells during pancreas development.
    Gouzi M; Kim YH; Katsumoto K; Johansson K; Grapin-Botton A
    Dev Dyn; 2011 Mar; 240(3):589-604. PubMed ID: 21287656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.
    Mio C; Conzatti K; Baldan F; Allegri L; Sponziello M; Rosignolo F; Russo D; Filetti S; Damante G
    Oncol Rep; 2018 Feb; 39(2):582-588. PubMed ID: 29251329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX4 cooperates with neurogenin 3 to regulate endocrine pancreas formation in mouse models.
    Xu EE; Krentz NA; Tan S; Chow SZ; Tang M; Nian C; Lynn FC
    Diabetologia; 2015 May; 58(5):1013-23. PubMed ID: 25652387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgene expression level and inherent differences in target gene activation determine the rate and fate of neurogenin3-mediated islet cell differentiation in vitro.
    Boretti MI; Gooch KJ
    Tissue Eng; 2007 Apr; 13(4):775-88. PubMed ID: 17355210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors.
    Haumaitre C; Lenoir O; Scharfmann R
    Mol Cell Biol; 2008 Oct; 28(20):6373-83. PubMed ID: 18710955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.